Artelo Biosciences, Inc. Common Stock earnings per share and revenue
On 12 nov 2025, ARTL reported earnings of -3.97 USD per share (EPS) for Q3 25, missing the estimate of -0.83 USD, resulting in a -374.65% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -8.16% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -1.60 USD, with revenue projected to reach -- USD, implying an decrease of -59.70% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
22 dic 2025 For Q4 25
Estimate
-$0.57
Actual
-$0.73
Sorpresa
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
19 dic 2025 For Q4 25
Estimate
-$0.25
Actual
-$0.19
Sorpresa
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
23 dic 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Sorpresa
+50.98%
Preguntas frecuentes
What were Artelo Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Artelo Biosciences, Inc. Common Stock reported EPS of -$3.97, missing estimates by -374.65%, and revenue of $0.00, 0% as expectations.
How did the market react to Artelo Biosciences, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -8.16%, changed from $1.96 before the earnings release to $1.80 the day after.
When is Artelo Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for 02 mar 2026.
What are the forecasts for Artelo Biosciences, Inc. Common Stock's next earnings report?
Based on 3
analysts, Artelo Biosciences, Inc. Common Stock is expected to report EPS of -$1.60 and revenue of -- for Q4 2025.